Glytec's Innovative Approach to Inpatient Diabetes Care Solutions
The Final Countdown for New CMS Glycemic Measures
167 Days to Prepare for the New Federal Reporting Requirements for Hypo- and Hyperglycemia
Glytec is a leading provider of an AI-powered technology platform dedicated to diabetes management, including its FDA-cleared Glucommander solution which integrates within Electronic Health Records (EHR) for inpatient glycemic management. With just 167 days left until the new Centers for Medicare & Medicaid Services (CMS) requirements go into effect, it’s imperative for hospitals to start making necessary preparations for these pivotal changes.
Preparing for the New Federal Mandates
The measurement period for the new reporting is set to commence soon, and hospitals must ensure they are equipped with the right tools, data systems, and workflows. This preparation is crucial not just for compliance, but also to prevent reductions in Medicare reimbursements that could impact financial viability starting in the upcoming fiscal year. Under the updated mandate, hospitals will need to report severe hypoglycemia (blood glucose levels below 40 mg/dL) and severe hyperglycemia (blood glucose levels above 300 mg/dL) as electronic clinical quality measures (eCQMs).
The Impact on Hospitalized Patients
These glycemic measures will affect a substantial portion of patients, specifically those who experience dysglycemia. Hospitalized individuals with diabetes or related conditions can significantly benefit from improved oversight and management of their blood sugar levels during their stay.
Patrick Cua, the CEO of Glytec, emphasizes the importance of this mandate, stating that it draws attention to the inpatient diabetes care sector. He notes that hospitals have an opportunity to enhance patient care and safety while also improving their financial health through better management practices.
Understanding the Burden of Glycemic Events
The call for new CMS reporting is largely due to the growing challenges related to diabetes prevalence and its complications. A significant volume of admitted patients (over one-third) require insulin therapy to control their blood glucose. Moreover, adverse events related to hypoglycemia occur in hospitals more than two million times annually, leading to increased healthcare costs and extended hospital stays. In fact, approximately $8 billion is attributed to these incidents, highlighting the need for robust glycemic management strategies.
Despite the widespread impact of these glycemic events, it is concerning that a considerable number of hospitals still do not actively track glucose management metrics or have automated systems to capture relevant data effectively. This lack of oversight contributes to inefficiencies and potential patient harm. Some facilities have attempted to create their own internal measurement solutions, but these often fall short of meeting industry standards and can create additional complications.
Advancing Diabetes Management Technology
The Glytec Technology Platform, utilized by over 400 hospitals, provides a dynamic solution for managing complex workflows associated with diabetes care—from hospital admission through to discharge. Built on a foundation of more than 100 patents, numerous clinical publications, and years of industry experience, the platform ensures reliable, AI-powered insulin dosing and management.
What Glytec Offers
As an FDA-cleared platform, Glytec's technology features:
- Advanced insulin dosing algorithms that undergo continuous clinical validation.
- Real-time dashboards that meet CMS reporting standards.
- Seamless integration with existing EHR systems, prioritizing cybersecurity and minimizing IT burdens.
- Access to Glytec’s extensive intellectual property, enhancing operational flexibility.
Avoiding Shortcomings of In-House Solutions
While some healthcare facilities have chosen to develop in-house tools for insulin management, such systems often lack essential clinical validation and may struggle to ensure user safety and interface functionality. This can lead to increased dosing errors. Moreover, the ongoing requirement for maintenance and updates can divert crucial IT resources away from other strategic goals essential for hospital operations.
The Urgent Need to Prepare
As the countdown to the CMS mandate continues, hospitals face the pressing task of selecting reliable partners to enhance their patient care capabilities. Engaging with proven solutions like Glytec’s technology not only mitigates risks associated with unsupported approaches but also promotes better healthcare outcomes.
About Glytec
Glytec stands out as an innovator in diabetes management, helping over 400 hospitals deliver collaborative care. Its flagship product, Glucommander, was the first cloud-based insulin management software to receive FDA clearance, facilitating smoother integration with EMRs and improving clinical decision-making with intelligent analytics and monitoring capabilities. Glytec remains committed to refining and enhancing the continuum of diabetes care, ensuring patients receive optimal treatment from the hospital to their homes.
Frequently Asked Questions
What are the new CMS glycemic measures?
The new CMS measures mandate reporting on severe hypoglycemia and hyperglycemia as electronic clinical quality measures.
How will hospitals be impacted by these measures?
Hospitals must adapt their diabetes care protocols to comply with the new regulations or face potential financial penalties.
What does Glytec provide for hospitals?
Glytec offers an FDA-cleared technology platform designed for efficient insulin management and improved patient outcomes.
Why are glycemic events a focus for hospitals?
Glycemic events can lead to significant patient harm and financial costs, prompting increased scrutiny and better management practices.
How can hospitals prepare for the CMS mandate?
Hospitals should invest in reliable technology solutions and start implementing necessary workflows well ahead of the deadline.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
